Double attack on blood disorder: could two drugs beat one for stubborn ITP?

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age ≥18 years, regardless of sex. 2. Clinically diagnosed with immune thrombocytopenia for at least 3 months prior to enrollment. Platelet count \<30×10⁹/L within 48 hours before the first dose of study drug. 3. Previous failure (ineffective, unable to maintain response, or relapse) to first-line standard corticosteroid therapy for ITP as recommended by guidelines. 4. Any prior emergency treatment for ITP (e.g., corticosteroids, platelet transfusion, intravenous immunoglobulin) must have been completed at least 2 weeks before the first dose. 5. Patients receiving maintenance corticosteroid therapy must be on a stable dose for at least 2 weeks prior to the first dose; patients receiving immunosuppressants (e.g., azathioprine, danazol, cyclosporine A, tacrolimus, sirolimus, etc.) must be on a stable dose for at least 4 weeks prior to the first dose; anti-CD20 antibody therapy must have been completed \>3 months prior. Understand the study procedures and voluntarily provide written informed consent. Exclusion Criteria: 1. Received anti-CD20 antibody therapy within 3 months. 2. Uncontrolled primary disease of vital organs, such as malignant tumors, liver failure, heart failure, renal failure, etc. 3. Positive for HIV. 4. Uncontrolled active viral or bacterial infections, including positive for hepatitis B, hepatitis C, cytomegalovirus, Epstein-Barr virus, or syphilis. 5. Extensive and severe bleeding, such as hemoptysis, upper gastrointestinal hemorrhage, intracranial hemorrhage, etc. 6. Currently have cardiac disease requiring treatment, arrhythmia, or hypertension poorly controlled as judged by the investigator. 7. Patients with thrombotic diseases such as pulmonary embolism, thrombosis, atherosclerosis, etc. 8. Patients with mental disorders who are unable to give informed consent or undergo study procedures and follow-up normally. 9. Patients whose toxic symptoms from prior treatment before enrollment have not yet resolved. 10. Other serious diseases that may limit the patient's participation in this study (e.g., poorly controlled diabetes; severe cardiac insufficiency; myocardial infarction, unstable arrhythmia, or unstable angina within the past 6 months; gastric ulcer; active autoimmune disease, etc.). 11. Pregnant women, suspected pregnancy (positive urinary human chorionic gonadotropin pregnancy test at screening), or lactating patients.